During clinical trials of new drugs pharmaceutical companies must be able to depend on strict adherence to therapy regimens. However, up to 50 percent of patients involved in clinical trials do not adhere to the prescribed dosage regimen, resulting in distorted outcomes such as insufficient drug efficacy or underestimated frequency of side effects and delayed time to market. To enhance therapy adherence in clinical trials, Schreiner MediPharm (Oberschleißheim, Germany) and AARDEX Group (Seraing, Belgium) offer an electronic solution for medication adherence monitoring enabling pharmaceutical companies to digitally monitor and manage medication intake of their trial participants.